Calliditas Therapeutics shares are trading higher after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce proteinuria in lgA nephropathy.
probably should have gotten to this the day before though, you would have gotten a gap up? why didn't you? probably because it closed under the MAs...
No comments:
Post a Comment